Mirum Pharmaceuticals, Inc. Comprehensive Income
Mirum Pharmaceuticals, Inc. (MIRM) reported Comprehensive Income of -$67.87 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$67.87M.
- Mirum Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$790.53M.
- Mirum Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$5.42M.
- Mirum Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $2.59M.
- Mirum Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$22.64M.
- Mirum Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$89.96M.
- Mirum Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$161.55M.
- Mirum Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$135.85M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 5 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 8 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$67.87M 10-Q · filed 2026-08-05 | -$858.41M 10-Q · filed 2026-08-05 | -$863.82M derived: sum of 3 quarters · filed 2026-08-05 | -$861.23M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | -$790.53M 10-Q · filed 2026-05-06 | -$795.95M derived: sum of 2 quarters · filed 2026-05-06 | -$793.36M derived: sum of 3 quarters · filed 2026-05-06 | -$798.61M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | -$5.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$2.83M derived: sum of 2 quarters · filed 2026-02-25 | -$8.08M derived: sum of 3 quarters · filed 2026-08-05 | -$22.64M 10-K · filed 2026-02-25 | ||
| 2025-09-30 | $2.59M 10-Q · filed 2025-11-04 | -$2.66M derived: sum of 2 quarters · filed 2026-08-05 | -$17.22M 10-Q · filed 2025-11-04 | -$42.31M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | -$5.25M 10-Q · filed 2026-08-05 | -$19.81M 10-Q · filed 2026-08-05 | -$44.90M derived: sum of 3 quarters · filed 2026-08-05 | -$57.73M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$14.56M 10-Q · filed 2026-05-06 | -$39.65M derived: sum of 2 quarters · filed 2026-05-06 | -$52.48M derived: sum of 3 quarters · filed 2026-05-06 | -$77.58M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | -$25.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$37.92M derived: sum of 2 quarters · filed 2026-02-25 | -$63.02M derived: sum of 3 quarters · filed 2026-02-25 | -$89.96M 10-K · filed 2026-02-25 | ||
| 2024-09-30 | -$12.84M 10-Q · filed 2025-11-04 | -$37.94M derived: sum of 2 quarters · filed 2025-11-04 | -$64.88M 10-Q · filed 2025-11-04 | -$97.43M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-06-30 | -$25.10M 10-Q · filed 2025-08-06 | -$52.04M 10-Q · filed 2025-08-06 | -$84.59M derived: sum of 3 quarters · filed 2026-02-25 | -$109.72M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-03-31 | -$26.94M 10-Q · filed 2025-05-07 | -$59.49M derived: sum of 2 quarters · filed 2026-02-25 | -$84.61M derived: sum of 3 quarters · filed 2026-02-25 | -$158.71M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2023-12-31 | -$32.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$57.68M derived: sum of 2 quarters · filed 2026-02-25 | -$131.78M derived: sum of 3 quarters · filed 2026-02-25 | -$161.55M 10-K · filed 2026-02-25 | ||
| 2023-09-30 | -$25.12M 10-Q · filed 2024-11-12 | -$99.22M derived: sum of 2 quarters · filed 2024-11-12 | -$129.00M 10-Q · filed 2024-11-12 | -$165.23M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | -$74.10M 10-Q · filed 2024-08-07 | -$103.88M 10-Q · filed 2024-08-07 | -$140.11M derived: sum of 3 quarters · filed 2025-02-26 | -$176.03M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | -$29.78M 10-Q · filed 2024-05-08 | -$66.01M derived: sum of 2 quarters · filed 2025-02-26 | -$101.93M derived: sum of 3 quarters · filed 2025-02-26 | -$128.92M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | -$36.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$72.15M derived: sum of 2 quarters · filed 2025-02-26 | -$99.14M derived: sum of 3 quarters · filed 2025-02-26 | -$135.85M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | -$35.92M 10-Q · filed 2023-11-02 | -$62.91M derived: sum of 2 quarters · filed 2023-11-02 | -$99.61M 10-Q · filed 2023-11-02 | -$42.09M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2022-06-30 | -$26.99M 10-Q · filed 2023-08-07 | -$63.70M 10-Q · filed 2023-08-07 | -$6.18M derived: sum of 3 quarters · filed 2024-03-15 | -$53.28M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2022-03-31 | -$36.70M 10-Q · filed 2023-05-04 | $20.82M derived: sum of 2 quarters · filed 2024-03-15 | -$26.29M derived: sum of 3 quarters · filed 2024-03-15 | -$70.19M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2021-12-31 | $57.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $10.42M derived: sum of 2 quarters · filed 2024-03-15 | -$33.49M derived: sum of 3 quarters · filed 2024-03-15 | -$84.11M 10-K · filed 2024-03-15 | ||
| 2021-09-30 | -$47.10M 10-Q · filed 2022-11-09 | -$91.01M derived: sum of 2 quarters · filed 2022-11-09 | -$141.62M 10-Q · filed 2022-11-09 | -$178.91M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | -$43.91M 10-Q · filed 2022-08-04 | -$94.52M 10-Q · filed 2022-08-04 | -$131.81M derived: sum of 3 quarters · filed 2022-08-04 | -$153.47M derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2021-03-31 | -$50.62M 10-Q · filed 2022-05-05 | -$87.91M derived: sum of 2 quarters · filed 2022-05-05 | -$109.56M derived: sum of 3 quarters · filed 2022-05-05 | -$132.47M derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2020-12-31 | -$37.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$58.94M derived: sum of 2 quarters · filed 2022-03-09 | -$81.85M derived: sum of 3 quarters · filed 2022-03-09 | -$103.32M 10-K · filed 2022-03-09 | ||
| 2020-09-30 | -$21.65M 10-Q · filed 2021-11-15 | -$44.56M derived: sum of 2 quarters · filed 2021-11-15 | -$66.02M 10-Q · filed 2021-11-15 | -$83.94M derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-06-30 | -$22.91M 10-Q · filed 2021-08-05 | -$44.37M 10-Q · filed 2021-08-05 | -$62.29M derived: sum of 3 quarters · filed 2021-08-05 | -$77.31M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | -$21.46M 10-Q · filed 2021-05-06 | -$39.38M derived: sum of 2 quarters · filed 2021-05-06 | -$54.40M derived: sum of 3 quarters · filed 2021-05-06 | -$67.93M derived: sum of 4 quarters · filed 2021-05-06 | ||
| 2019-12-31 | -$17.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$32.94M derived: sum of 2 quarters · filed 2021-03-09 | -$46.47M derived: sum of 3 quarters · filed 2021-03-09 | -$52.42M 10-K · filed 2021-03-09 | ||
| 2019-09-30 | -$15.02M 10-Q · filed 2020-11-12 | -$28.55M derived: sum of 2 quarters · filed 2020-11-12 | -$34.50M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$13.53M 10-Q · filed 2020-08-06 | -$19.49M 10-Q · filed 2020-08-06 | ||||
| 2019-03-31 | -$5.96M 10-Q · filed 2020-05-07 | |||||
| 2018-12-31 | -$17.35M 10-K · filed 2020-03-12 | |||||
| 2018-09-30 | -$67.00K 10-Q · filed 2019-11-06 | -$77.00K 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |